Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for low-responders after bariatric surgery
2020-000548-71Phase 4Terminated
- Sponsor
- Nederlandse Obesitas Kliniek
- Start
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, single-arm trial of liraglutide in class III obesity, sponsored by Nederlandse Obesitas Kliniek. Primary endpoint: Percent total weight loss at 9 months after surgery. Started Dec 2020; status: terminated.
02
Drugs
03
Conditions
class III obesity
Beyond the preview
Go deeper on 2020-000548-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000548-71.